NCT03406091

Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients

Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients: Prospective Product Registry

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 300 (actual)
• Sponsor: Fondazione EMN Italy Onlus · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The study is an italian multicentric and will be conducted in 20 centers. The aim of this study is to evaluate poor mobilizer (PM) rate in newly diagnosed MM patients who are mobilized with cyclophosphamide and G-CSF and plerixafor on demand. Plerixafor is a specific reversible inhibitor of the chemokine receptor CXCR4 and prevents the binding of its ligand stromal cell derived factor SDF-1α also known as CXCL12, thereby releasing hematopoietic stem cells into the circulation.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Plerixafor	Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) \[3\]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.

Timeline

• Start date: 2015-11-26
• Primary completion: 2021-01-19
• Completion: 2024-01-17
• First posted: 2018-01-23
• Last updated: 2024-02-20

Locations

1 site across 1 country: Italy